IASLC TTLC 2024 | Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors

Rajwanth Veluswamy, MD, Icahn School Of Medicine At Mount Sinai, New York, NY, comments on the utility of pan-RAF inhibitors in solid tumors. Multiple pan-RAF inhibitors are under investigation in clinical trials, with the aim of finding the most effective dose. The aforementioned trials will additionally elucidate which specific mutations will respond the best to these pan-RAF inhibitors. Dr Veluswamy additionally highlights potential combination strategies to address resistance to current inhibitors. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.